Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

(2012) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Parenteral Anticoagulants

(2012) David A. Garcia et al.   CHEST

Oral Anticoagulant Therapy

(2012) Walter Ageno et al.   CHEST

Evidence-Based Management of Anticoagulant Therapy

(2012) Anne Holbrook et al.   CHEST

Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups

(2012) G. F. PINEO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Anticoagulating obese patients in the modern era

(2011) Jignesh P. Patel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Error in body weight estimation leads to inadequate parenteral anticoagulation

(2010) Leon Gustavo dos Reis Macedo et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Dosing of Unfractionated Heparin in Obese Patients with Venous Thromboembolism

(2010) Adam N. Hurewitz et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings

(2009) Edith A Nutescu et al.   ANNALS OF PHARMACOTHERAPY

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overweight, Obesity, and the Risk of Recurrent Venous Thromboembolism

(2008) Sabine Eichinger   ARCHIVES OF INTERNAL MEDICINE

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Atrial fibrillation and obesity—results of a meta-analysis

(2007) Nikolas Wanahita et al.   AMERICAN HEART JOURNAL

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics

(2007) B.J. Anderson et al.   Annual Review of Pharmacology and Toxicology